Investors pile into Viva Biotech’s Hong Kong IPO as they are confident of the R&D services provider’s business model

The retail tranche of the Shanghai-based company’s HK$1.37 billion (US$176 million) IPO handily beat the 90.8 times subscription interest seen in vaccines developer Cansino Biologics’ offering in …
( read original story …)

---